This list is an analysis based on recent market events. It's not an investment recommendation.
About
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange New Horizon Health Limited stocks are traded under the ticker NHZHY.
What is New Horizon Health Limited revenue for the last year?▼
New Horizon Health Limited revenue for the last year amounts to 111.88M USD.
What is New Horizon Health Limited net income for the last year?▼
NHZHY net income for the last year is -11.77M USD.
How many employees does New Horizon Health Limited have?▼
As of October 5, 2026, the company has 1,041 employees.
In which sector is New Horizon Health Limited located?▼
New Horizon Health Limited operates in the Other sector.
When did New Horizon Health Limited complete a stock split?▼
New Horizon Health Limited has not had any recent stock splits.
Where is New Horizon Health Limited headquartered?▼
New Horizon Health Limited is headquartered in Hangzhou, Germany.